Aclaris Therapeutics, Inc.
ACRS
$1.75
-$0.06-3.32%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -40.44% | 10.96% | -6,375.65% | 74.07% | 62.85% |
| Total Depreciation and Amortization | -52.89% | -47.33% | -37.28% | -18.26% | 11.01% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 47.05% | -21.56% | 571.26% | -50.26% | -38.21% |
| Change in Net Operating Assets | 116.21% | 78.51% | -107.49% | 909.45% | -227.37% |
| Cash from Operations | 18.90% | 37.27% | -32.20% | 189.59% | 40.34% |
| Capital Expenditure | -250.00% | 68.15% | 100.00% | 100.00% | 106.06% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 836.63% | 12.93% | -1,210.29% | -91.43% | 96.46% |
| Cash from Investing | 848.81% | 13.58% | -1,275.14% | -91.41% | 96.57% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | 9,042.86% | 113.33% | -- |
| Repurchase of Common Stock | 18.18% | -400.00% | -- | 90.20% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -515.86% | -- | -- |
| Cash from Financing | 18.18% | -400.00% | 152,104.08% | 125.29% | -100.04% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 61.91% | 243.35% | -2,854.30% | 214.54% | 4.16% |